The role of zidovudine in development of lipoatrophy

AIDS Reader

Volumn 15, Issue 11, 2005, Pages

  Moyle, Graeme J ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV AIDS; Lipoatrophy; Zidovudine

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EMTRICITABINE; INDINAVIR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LAMIVUDINE; LOPINAVIR; MITOCHONDRIAL DNA; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE; ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BODY COMPOSITION; BODY FAT; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; REVIEW; RISK; SUBCUTANEOUS FAT; ADIPOSE TISSUE; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; HIV ASSOCIATED LIPODYSTROPHY; MOUSE; RANDOMIZED CONTROLLED TRIAL; RAT;

ADIPOSE TISSUE; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS; RATS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 33644653238     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
2. Dube M, Zachin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral naive subjects randomised to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz or both: A5005s, a substudy of ACTG 384. Antivir Ther. 2002;7:L18.
3. Shlay JC, Visnegarwala F, Bartsch G, et al; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
4. Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
5. Carr A, Law M; HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33:571-576.
6. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS. 2004;18:2127-2136.
7. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther. 2004;9:911-920.
8. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther. 2005;10:207-213.
9. Maisonneuve C, Igoudjil A, Begriche K, et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther. 2004;9:801-810.
10. Goetzman ES, Tian L, Nagy TR, et al. HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses. 2003;19:1141-1150.
11. Deveaud C, Beauvoit B, Hagry S, et al. Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy? Biochem Pharmacol. 2005;70:90-101.
12. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005;191:1686-1696.
13. Pace CS, Martin AM, Hammond EL, et al. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003;8:323-331.
14. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329-1338.
15. Jones S, Qazi N, Morelese J, et al. Mitochondrial toxicity in HIV patients with lipoatrophy on stavudine and zidovudine containing regimens. J Acquir Immune Defic Syndr. In press.
16. van der Valk M, Casula M, Weverling GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385-393.
17. Blanco F, Garcia-Benayas T, Jose de la Cruz J, et al. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials. 2003; 4:11-19.
18. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Oz-Combo 1 and 2. HIV Clin Trials. 2003;4:252-261.
19. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34:649-657.
20. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-2454.
21. Podzamczer D, Ferrer E, Sanchez P, et al. A randomized comparison between abacavir and stavudine, both combined with lamivudine/efavirenz, in antiretroviral-naive patients: final 96-week results of the ABCDE study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract 587.
22. Nolan D, James I, McKinnon E, et al. Effect of stavudine, zidovudine and HIV protease inhibitor therapy on subcutaneous leg fat wasting in HIV-infected males-a longitudinal study. Presented at the 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HW; September 22-25, 2002; San Diego. Abstract 28.
23. Pozniak AL, Gallant JE, DeJesus E, et al. Superior outcome for tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral naive patients. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro. Abstract WeOa0202.
24. De Ruiter A, Pozniak AL, Staszewski S, et al. Long-term safety and efficacy of tenofovir DF (TDF) versus stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naive women: 144-week results. Presented at the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1083.
25. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;88:207-215.
26. Moyle GJ, Baldwin C, Landroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003; 33:22-28.
27. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
28. Moyle GJ, Sabin C, Cartledge J, et al. A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. Presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract LB44.